Previous 10 | Next 10 |
Summary Avanos Medical's recent acquisition of the TriVisc portfolio creates an interesting debate for those following the hyaluronic acid market. We are holders of a competing name and so it's interesting to compare both offerings. I also demonstrate there's been a disconnect...
Summary Bioventus came in with another set of strong numbers in Q2. We reiterate the buy thesis on BVS and note there are numerous idiosyncratic risk premia on offer. The company has sorted its transaction of CartiHeal. Rate buy on $9.35 price target aiming for December 20...
DURHAM, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healt...
Image source: The Motley Fool. Bioventus Inc. (NASDAQ: BVS) Q2 2022 Earnings Call Aug 11, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Robb...
The following slide deck was published by Bioventus Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Bioventus Inc. 2022 Q2 - Results - Earnings Call Presentation
Bioventus press release ( NASDAQ: BVS ): Q2 Non-GAAP EPS of $0.10 misses by $0.06 . Revenue of $140.3M (+27.8% Y/Y) beats by $1.97M . FY Guidance: Net sales of $547.5 million to $562.5 million, representing year-over-year growth of approximately 27% to 31...
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022. Q2 Financial Summary & Recent ...
The U.S Food and Drug Administration (FDA) granted 510(k) clearance to Bioventus' ( NASDAQ: BVS ) neXus SonaStar Elite handpiece for resection of tumors. The company said the SonaStar Elite (SSE) handpiece is powered by the neXus Ultrasonic Surgical Aspirator Syste...
Innovative New Handpiece Addition to the Nexus Ultrasonic Generator Significantly Expands Company’s Offering in Neurosurgery Ablation Procedures DURHAM, N.C., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the ...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before t...
2024-05-26 21:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...